Canaccord analyst Jason Mills believes Edwards Lifesciences shares should react positively to the news released in its 10K that it would resume clinical activity with its EW-CardiAQ TMVR platform following completion of validation testing. This comes on the heels of management voluntarily pausing the trials to perform design testing on a specific valve function. Mills recommends investors be more aggressive near-term as the restart of patient screening should help ally concerns that a material valve change may have been warranted. Mills reiterated his Buy rating and $140 price target on Edwards shares.